EVOXAC Oral Solution: Who Benefits From FDA Approval?

Why does a liquid treatment for Sjögren's dry mouth matter?

Cosette's October 20 announcement introduces an oral solution containing cevimeline, the active ingredient already used in EVOXAC capsules. The company developed the formulation for adults with Sjögren's-related dry mouth, including those who have difficulty swallowing capsules. Its practical significance is an additional administration option; a formulation change alone does not establish greater effectiveness. [Cosette announcement](https://www.biospace.com/press-releases/cosette-pharmaceuticals-announces-fda-approval-of-evoxac-cevimeline-hcl-oral-solution-marking-cosettes-first-new-drug-application-nda-approval)

Sjögren's is an autoimmune disease in which immune cells damage glands that produce saliva and tears. Reduced saliva can make chewing and swallowing uncomfortable, alter taste and increase susceptibility to tooth decay and oral infections. Treating dryness therefore addresses a problem that can affect eating and everyday comfort. The disease can also affect other organs, so relief of mouth symptoms represents only one part of care. [National Institute of Dental and Craniofacial Research](https://www.nidcr.nih.gov/health-info/sjogrens-disease)

What does clinical research show about cevimeline?

Cevimeline activates muscarinic receptors, stimulating secretions from glands including the salivary glands. The capsule prescribing information describes a six-week randomized, double-blind trial involving 75 participants. Among those assigned 30 mg three times daily, 76% reported improved dry-mouth symptoms, compared with 35% receiving placebo. These figures concern the earlier capsule evidence, not a new trial comparing the liquid with capsules. [EVOXAC capsule prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dac32a9b-05b8-42c2-9a29-d885a9279456)

The same label reports two longer studies with differing results: one found significant improvement in patients' overall assessment of dryness, while another did not, despite increased salivary flow. This distinction matters because producing more saliva and feeling substantially better are related but separate outcomes. The evidence supports a potential symptomatic benefit while showing that individual responses vary. [Clinical studies in the prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dac32a9b-05b8-42c2-9a29-d885a9279456)

What safety precautions and dental care remain important?

Cevimeline can cause sweating and nausea. Its established prescribing information contraindicates use with uncontrolled asthma, cevimeline hypersensitivity, acute iritis or narrow-angle glaucoma, and advises caution with significant cardiovascular disease. [Prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dac32a9b-05b8-42c2-9a29-d885a9279456)

Dental protection remains essential even when the mouth feels less dry. Sjögren's oral-care guidelines published in the Journal of the American Dental Association strongly recommend topical fluoride for patients with dry mouth. The guideline authors also identified a gap between evidence that treatments increase saliva and evidence that they prevent cavities. That distinction argues against treating symptom improvement as proof that teeth are adequately protected. A dental prevention plan should continue alongside medication. [Sjögren's dental-care guidelines](https://pubmed.ncbi.nlm.nih.gov/26762707/)

The National Institute of Dental and Craniofacial Research recommends regular dental examinations, fluoride toothpaste and discussion with a dentist about additional fluoride protection. Small, frequent sips of water can also help with comfort. These measures address continuing needs that a new formulation does not eliminate. [NIDCR guidance](https://www.nidcr.nih.gov/health-info/sjogrens-disease)